p53 and MDM2 isoforms in blood from lung cancer patients

Experimental Lung Research

Volumn 33, Issue 5, 2007, Pages 245-258

  Gonzalez Avila, Georgina ^a   Biol, Javier Delgado ^a   Martínez, Luis M ^a   Ramos, Carlos ^a   Sommer, Bettina ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

Lung cancer; MDM2; MDM2 splicing transcripts; Oncogene; p53

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LUNG ADENOCARCINOMA; MALE; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ACTINS; ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34447314439     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.1080/01902140701481112     Document Type: Article

References (23)

1. Osada H, Takahashi T: Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene. 2002;21:7421-7434.
2. Giaccone G: Oncogenes and antioncogenes in lung tumorigenesis. Chest. 1996;109:130S-134S.
3. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature. 2000;408:307-310.
4. Honda R, Tanaka H, Yasuda H: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997;420:25-27.
5. Shieh SY, Ikeda M, Taya Y, Prives C: DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 1997;91:325-334.
6. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science. 1991;253:49-53.
7. Robles AI, Linke SP, Harris CC: The p53 network in lung carcinogenesis. Oncogene. 2002;21:6898-6907.
8. Aikawa H, Sato M, Fujimura S, Takahashi H, Endo Ch, Sakurada A, Chen Y, Kondo T, Tanita T, Matsumura Y, Saito Y, Sagawa M: MDM2 expression is associated with progress of disease and WAF1 expression in resected lung cancer. Int J Mol Med. 2000;5:631-633.
9. Higashiyama M, Doi O, Kodama K, Yokouchi H, Kasugai T, Ishiguro S, Takami K, Nakayama T, Nishisho I: MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognosis marker in patients without p53 protein accumulation. Br J Cancer. 1997;75:1302-1308.
10. Ko JL, Cheng YW, Chang SL, Su J-M, Chen Ch-Y, Lee H: MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer. Int J Cancer. 2000;89:265-270.
11. Mountain CF: Revisions in the international system for staging lung cancer. Chest. 1997;111: 1710-1717.
12. Jackman DM, Johnson BE: Small-cell lung cancer. Lancet. 2005;366:1385-1396.
13. Smith PK, Krohn RI, Hermanson GT, Malia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC: Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150:76-85.
14. Vigano A, Bruera E, Jhangri GS, Newman SC, Fields AL, Suarez-Almazor ME: Clinical survival predictors in patients with advanced cancer. Arch Intern Med. 2000;160:861-868.
15. McMillan DC, Watson WS, O'Gorman P, Preston T, Scott HR, McArdle CS: Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer. 2001;39:210-213.
16. Koga T, Hashimoto S, Sugio K, Yoshino I, Nakagawa K, Yonemitsu Y, Sugimachi K, Sueishi K: Heterogeneous distribution of p53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with p53 gene mutation. Int J Cancer. 2001;95:232-239.
17. Mori S, Ito G, Usami N, Yoshioka H, Ueda Y, Kodama Y, Takahashi M, Fong KM, Shimokata K, Sekido Y: p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma. Cancer. 2004;100:1673-1682.
18. Wang Y-Ch, Lin R-K, Tan Y-H, Chen J-T, Chen Ch-Y, Wang Y-C: Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small cell lung cancer. J Clin Oncol. 2005;23:154-164.
19. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J: Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med. 1996;2:912-917.
20. Lukas J, Gao D-Q, Keshmeshian M, Wen WH, Tsao-Wei D, Rosenberg SH, Press MF: Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res. 2001;61:3212-3219.
21. Perry ME, Mendrysa SM, Saucedo LJ, Tannous P, Holubar M: p76 (MDM2) inhibits the ability of p90 (MDM2) to destabilize p53. J Biol Chem. 2000;275:5733-5738.
22. Gorgoulis VG, Zoumpourlis V, Rassidakis GZ, Karameris A, Rassidakis AN, Spandidos DA, Kittas CH: A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma. J Pathol. 1996;180:129-137.
23. ARF inactivation are two mutually exclusive events in primary human lung tumors. Oncogene. 2002;21:2750-2761.